Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Crispr Therapeutics AG (CRSP) vs PayPal Holdings, Inc. (PYPL) Price & Performance

Crispr Therapeutics AGTrade
PayPal Holdings, Inc.Trade

Price performance (Past 24H)

Key statistics

Crispr Therapeutics AG vs PayPal Holdings, Inc. — how do they compare? Crispr Therapeutics AG trades at $54.08 (market cap $5.17B), while PayPal Holdings, Inc. trades at $58.21 (market cap $50.53B). The key difference: PayPal Holdings, Inc. is far larger — about 9.8× Crispr Therapeutics AG's market cap, and PayPal Holdings, Inc. pays a 0.95% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.

CRSPPYPL
Market Cap
$5.17B$50.53B
Sector
HealthFinancials
52-Week High
$76.78$76.13
52-Week Low
$44.34$39.08
Enterprise Value
$3.59B$52.68B
Dividend Yield
0.95%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Crispr Therapeutics AG

CRISPR Therapeutics (CRSP) trades at $53.52, up 3.64% in the last session, with a bullish technical outlook from moving averages but overbought RSI signals. The company reported a Q2 2026 loss of $0.94 per share, beating estimates, while revenue growth is driven by Casgevy sales. Analyst consensus is a Buy with a $76 price target, reflecting optimism for pipeline catalysts.

The outlook is supported by strong product sales and clinical progress, but significant risks include persistent negative margins, high cash burn, and reliance on pipeline success. Investors face a high-risk, high-reward scenario with the stock trading near resistance levels amid volatile earnings history.

PayPal Holdings, Inc.

No Aura AI signal available yet.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Crispr Therapeutics AG

CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.

Read more on CRSP

About PayPal Holdings, Inc.

PayPal Holdings, Inc. operates as a technology platform company that enables digital and mobile payments on behalf of consumers and merchants. The Company offers online payment solutions. PayPal Holdings serves customers worldwide.

Read more on PYPL